These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 23453477)

  • 1. Rheumatoid factor does not predict response to TNF antagonists in rheumatoid arthritis: three centers experience.
    Salgado E; Campos J; Moreira-Navarrete V; Mulero J; Navarro F; Pérez-Pampín E; Carmona L; Gómez-Reino J
    Joint Bone Spine; 2013 Jul; 80(4):438-40. PubMed ID: 23453477
    [No Abstract]   [Full Text] [Related]  

  • 2. Rheumatoid factor appearance after tocilizumab treatment seems to predict bad therapeutical response in rheumatoid arthritis.
    Faillace C; de Carvalho JF
    Rheumatol Int; 2013 Jul; 33(7):1909-10. PubMed ID: 22441966
    [No Abstract]   [Full Text] [Related]  

  • 3. Rheumatoid factor and response to TNF antagonists in rheumatoid arthritis: systematic review and meta-analysis of observational studies.
    Salgado E; Maneiro JR; Carmona L; Gómez-Reino J
    Joint Bone Spine; 2014 Jan; 81(1):41-50. PubMed ID: 23731644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNFalpha agents failed are associated with response to rituximab in rheumatoid arthritis].
    Quartuccio L; Salvin S; Saracco M; Lombardi S; Fabris M; Mansutti E; Maset M; Pellerito S; De Vita S
    Reumatismo; 2009; 61(3):182-6. PubMed ID: 19888503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased pretreatment serum IFN-β/α ratio predicts non-response to tumour necrosis factor α inhibition in rheumatoid arthritis.
    Wampler Muskardin T; Vashisht P; Dorschner JM; Jensen MA; Chrabot BS; Kern M; Curtis JR; Danila MI; Cofield SS; Shadick N; Nigrovic PA; St Clair EW; Bingham CO; Furie R; Robinson W; Genovese M; Striebich CC; O'Dell JR; Thiele GM; Moreland LW; Levesque M; Bridges SL; Gregersen PK; Niewold TB
    Ann Rheum Dis; 2016 Oct; 75(10):1757-62. PubMed ID: 26546586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis.
    Bobbio-Pallavicini F; Caporali R; Alpini C; Avalle S; Epis OM; Klersy C; Montecucco C
    Ann Rheum Dis; 2007 Mar; 66(3):302-7. PubMed ID: 17079248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the RISING study.
    Takeuchi T; Miyasaka N; Inui T; Yano T; Yoshinari T; Abe T; Koike T
    Arthritis Res Ther; 2017 Sep; 19(1):194. PubMed ID: 28865493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Escalated conventional therapy for rheumatoid arthritis patients.
    Smith MD
    Rheumatology (Oxford); 2004 Sep; 43(9):1199; author reply 1199-1200. PubMed ID: 15317963
    [No Abstract]   [Full Text] [Related]  

  • 9. Association of anti-CCP positivity and carriage of TNFRII susceptibility variant with anti-TNF-α response in rheumatoid arthritis.
    Vasilopoulos Y; Bagiatis V; Stamatopoulou D; Zisopoulos D; Alexiou I; Sarafidou T; Settas L; Sakkas L; Mamouris Z
    Clin Exp Rheumatol; 2011; 29(4):701-4. PubMed ID: 21813066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of cartilage oligomeric matrix protein as biomarker predicting abatacept response in rheumatoid arthritis patients with insufficient response to a first anti-TNFα treatment.
    Nguyen MVC; Adrait A; Baillet A; Trocmé C; Gottenberg JE; Gaudin P
    Joint Bone Spine; 2019 May; 86(3):401-403. PubMed ID: 30243783
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical remission following treatment with tumour necrosis factor-alpha antagonists is not accompanied by changes in asymmetric dimethylarginine in patients with rheumatoid arthritis.
    Sandoo A; Dimitroulas T; Toms TE; Hodson J; Veldhuijzen van Zanten JJ; Smith JP; Kitas GD
    Clin Biochem; 2012 Nov; 45(16-17):1399-403. PubMed ID: 22820438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An exploratory study to determine whether infliximab modifies levels of rheumatoid factor and antibodies to cyclic citrullinated peptides in rheumatoid arthritis patients.
    Martínez-Estupiñán L; Hernández-Flórez D; Janta I; Ovalles-Bonilla JG; Nieto JC; González-Fernández CM; Del Río T; Monteagudo I; López-Longo FJ; Naredo E; Valor L
    Clin Exp Rheumatol; 2018; 36(1):88-93. PubMed ID: 28850020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis.
    Quartuccio L; Fabris M; Salvin S; Atzeni F; Saracco M; Benucci M; Cimmino M; Morassi P; Masolini P; Pellerito R; Cutolo M; Puttini PS; De Vita S
    Rheumatology (Oxford); 2009 Dec; 48(12):1557-9. PubMed ID: 19789202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement system and rheumatoid arthritis: relationships with autoantibodies, serological, clinical features, and anti-TNF treatment.
    Di Muzio G; Perricone C; Ballanti E; Kroegler B; Greco E; Novelli L; Conigliaro P; Cipriani P; Giacomelli R; Perricone R
    Int J Immunopathol Pharmacol; 2011; 24(2):357-66. PubMed ID: 21658310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis.
    Chen HA; Lin KC; Chen CH; Liao HT; Wang HP; Chang HN; Tsai CY; Chou CT
    Ann Rheum Dis; 2006 Jan; 65(1):35-9. PubMed ID: 15975966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibodies against mutated citrullinated vimentin fail to predict anti-TNFalpha treatment response in rheumatoid arthritis.
    Dejaco C; Duftner C; Klotz W; Schirmer M; Herold M
    Scand J Rheumatol; 2009; 38(1):66-7. PubMed ID: 18759163
    [No Abstract]   [Full Text] [Related]  

  • 17. Application of omics in predicting anti-TNF efficacy in rheumatoid arthritis.
    Xie X; Li F; Li S; Tian J; Chen JW; Du JF; Mao N; Chen J
    Clin Rheumatol; 2018 Jan; 37(1):13-23. PubMed ID: 28600618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry.
    Ørnbjerg LM; Østergaard M; Bøyesen P; Krogh NS; Thormann A; Tarp U; Poulsen UE; Espesen J; Schlemmer A; Graudal N; Kollerup G; Jensen DV; Madsen OR; Glintborg B; Christensen T; Lindegaard H; Bøhme W; Hansen A; Andersen AR; Hetland ML
    J Rheumatol; 2014 Dec; 41(12):2352-60. PubMed ID: 25274894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TNFRII polymorphism is associated with response to TNF blockers in rheumatoid arthritis patients seronegative for ACPA.
    Pers YM; Cadart D; Rittore C; Ravel P; Daïen V; Fabre S; Jorgensen C; Touitou I
    Joint Bone Spine; 2014 Jul; 81(4):370-2. PubMed ID: 24462126
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluation of inflammatory biomarkers and the ratio of hemoglobin-red cell distribution width in patients with rheumatoid arthritis treated with tumor necrosis factor-alpha inhibitors.
    Yetişir A; Sariyildiz A; Türk İ; Coskun Benlidayi I
    Clin Rheumatol; 2024 Jun; 43(6):1815-1821. PubMed ID: 38622428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.